Nasdaq
$48.48▼ 0.47%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.44BShares out 29.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 10.2After-hours26.10.03 06:474Ownership#●●●
ANAPTYSBIO, INC
AnaptysBio, Inc. director Hollings Renton has filed a Power of Attorney appointing Christopher Murphy, Dave McKeon, and Dan Faga as attorneys-in-fact to execute and file Form 3, 4, and 5 reports under Section 16(a) of the Exchange Act. This filing serves as an administrative measure to facilitate compliance with insider trading reporting requirements.…more
$48.48-0.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1After-hours26.10.02 05:07144Ownership
ANAPTYSBIO, INC
Renton Hollings, an insider at AnaptysBio, Inc., has filed a Form 144 regarding the proposed sale of company securities. This filing serves as a formal notification of the insider's intent to dispose of shares.…more
$48.48-0.47%vs prev closeView filingShare - 9.21After-hours26.09.22 05:2310-KTEarnings
ANAPTYSBIO, INC
AnaptysBio has filed its transition report (Form 10-KT) for the six-month period ended June 30, 2026. Key developments include the appointment of Chris Murphy as the new CFO via a consulting agreement and the execution of a sublease agreement for its San Diego office space with First Tracks Biotherapeutics.…more
$48.48-0.47%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoRegular26.10.20 03:18Bullish#●●●#●●●
AnaptysBio's Jemperli Receives FDA Approval for Rectal Cancer
Jemperli, for which AnaptysBio holds licensing rights, has received FDA approval as an immunotherapy for MSI-H/dMMR locally advanced rectal cancer. This approval expands the treatment landscape for eligible patients while Anaptys continues to manage the associated royalty collaborations.…more
$48.48-0.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.21After-hours26.09.22 05:55
●●●●●●●● ●●●●● ●●●●●●
AnaptysBio reported a Q2 loss per share of $0.11, significantly beating the analyst consensus of $0.46. Quarterly revenue reached $27.488 million, surpassing expectations and showing growth compared to the same period last year.…more
$48.48-0.47%vs prev closeShareBenzinga - 9.21After-hours26.09.22 05:15
●●●●●●●● ●●●●● ●●●●●●
AnaptysBio reported a profit in Q2 driven by increased Jemperli royalty revenue and tax benefits. The company's future valuation remains contingent on the outcome of ongoing litigation with GSK and upcoming regulatory decisions for partner-developed drugs.…more
$48.48-0.47%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report